© 2008 Alexis Corporation
APO-54N-028 Revised 02-Apr-08
Free Osteoprotegerin (human) Detection Set [For ELISA Application]
Add to Clipboard
SYNONYMS Free OPG (human) Detection Set [For ELISA Application]
Free TNFRSF 11B (human) Detection Set [For ELISA Application]
Free Osteoclastogenesis Inhibitory Factor (human) Detection Set [For ELISA Application]
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY OPG
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
APO-54N-028-KI01   1 Set 540.00 USD Add To Cart
Product Specification
SENSITIVITY: 2pg/ml (range 0 to 250 pg/ml).
QUANTITY: 5x96 wells.
KIT/SET CONTAINS: 1 vial Standard (lyophilized) (STD).
1 vial Coating Antibody (COAT).
1 vial Detection Antibody (DET).
APPLICATION: For the quantitative determination of human free osteoprotegerin (not bound to RANKL or TRAIL) in cell culture supernatant, plasma and serum.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
General Information
OPG (Osteoprotegerin; also called Osteoclastogenesis Inhibitory Factor or TNFRSF11B) is a secreted member of the TNF (Tumor necrosis factor) receptor superfamily of proteins [1]. OPG, composed of 380 amino acids, is expressed as monomer and secreted as disulphide-homodimeric protein [2]. Produced by numerous cell types and tissues, its expression pattern targets the skeletal, immune, and vascular systems. Osteoblasts secrete OPG that protects the skeleton from excessive bone resorption by acting as a decoy receptor for the ligand nuclear factor-κB ligand (RANKL), preventing it from interacting with its receptor RANK [3]. OPG/RANK/RANKL molecular triumvirat plays a pivotal function in the regulation of the immune system through dendritic cells [4]. OPG-deficient mice exhibit severe osteoporosis and vascular calcification of the aorta and renal arteries [5]. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD), a bone disease [6]. OPG also functions as a soluble receptor for the TNF ligand TRAIL (TNF-related apoptosis-inducing ligand) preventing it to activate apoptotic signaling cascase and therefore providing cancer cells with a survival advantage [7].
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link O00300: Osteoprotegerin (human)
General Literature References
[1] Biology of RANK, RANKL, and osteoprotegerin: B.F. Boyce & L. Xing; Arthritis Res. Ther. 9 Suppl 1, S1 (2007) Abstract
[2] Osteoprotegerin: a novel secreted protein involved in the regulation of bone density: W.S. Simonet, et al.; Cell 89, 309 (1997) Abstract
[3] Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation: D.L. Lacey, et al.; Cell 93, 165 (1998) Abstract
[4] RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases: M. Baud huin, et al.; Cell Mol. Life Sci. 64, 2334 (2007) Abstract
[5] Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis: H. Min, et al.; J. Exp. Med. 192, 463 (2000) Abstract
[6] Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling: M.P. Whyte; Ann. N. Y. Acad. Sci. 1068, 143 (2006) Abstract
[7] Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL: J.G. Emery, et al.; J. Biol. Chem. 273, 14363 (1998) Abstract; Full Text
Further Categories Containing This Product:
ELISA & EIA Kits
 
 
© 2008 ALEXIS Corporation, Privacy Policy, Disclaimer, Feedbackanother CS2 website